Deep learning classifies Alzheimer’s for personalized diagnosis, risk prediction

An AI algorithm has slightly outperformed neurologists at identifying or ruling out Alzheimer’s disease from MRI brain scans combined with demographic information and neuropsychological test results.

Developed by researchers at Boston University, the novel deep learning model is described in an open-access study running in Brain.

In internal coverage of the science published by the school, computational biomedicine specialist Vijaya Kolachalama, PhD, and colleagues suggest the study results show the field is closing in on the ability to predict Alzheimer’s risk at the point of care.

“If we have accurate tools to predict the risk of Alzheimer’s disease that are readily available and can use routinely available data such as a brain MRI scan, [the technology] will have the potential to assist clinical practice, especially in memory clinics.”

Click here to read the news item and here for the study.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.